{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:59:06Z","timestamp":1784660346130,"version":"3.55.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Essential core pathways of cellular biology are preserved throughout evolution, highlighting the importance of these pathways for both bacteria and human cancer cells alike. Cell viability requires a proper balance between protein synthesis and degradation in order to maintain integrity of the proteome. Proteasomes are highly intricate, tightly regulated multisubunit complexes that are critical to achieve protein homeostasis (proteostasis) through the selective degradation of misfolded, redundant and damaged proteins. Proteasomes function as the catalytic core of the ubiquitin-proteasome pathway (UPP) which regulates a myriad of essential processes including growth, survival, differentiation, drug resistance and apoptosis. Proteasomes recognize and degrade proteins that have been marked by covalently attached poly-ubiquitin chains. Deregulation of the UPP has emerged as an essential etiology of many prominent diseases, including cancer. Proteasome inhibitors selectively target cancer cells, including those resistant to chemotherapy, while sparing healthy cells. Proteasome inhibition has emerged as a transformative anti-myeloma strategy that has extended survival for certain patient populations from 3 to 8 years. The structural architecture and functional activity of proteasomes is conserved from <jats:italic>Archaea<\/jats:italic> to humans to support the concept that proteasomes are actionable targets that can be inhibited in pathogenic organisms to improve the treatment of infectious diseases. Proteasomes have an essential role during all stages of the parasite life cycle and features that distinguish proteasomes in pathogens from human forms have been revealed. Advancement of inhibitors that target <jats:italic>Plasmodium<\/jats:italic> and <jats:italic>Mycobacterial<\/jats:italic> proteasomes is a means to improve treatment of malaria and tuberculosis. In addition, PIs may also synergize with current frontline agents support as resistance to conventional drugs continues to increase. The proteasome represents a highly promising, actionable target to combat infectious diseases that devastate lives and livelihoods around the globe.<\/jats:p>","DOI":"10.3389\/fcimb.2022.925804","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T15:52:37Z","timestamp":1657209157000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes"],"prefix":"10.3389","volume":"12","author":[{"given":"James J.","family":"Ignatz-Hoover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","article-title":"PSMB8 Encoding the \u03b25i Proteasome Subunit is Mutated in Joint Contractures, Muscle Atrophy, Microcytic Anemia, and Panniculitis-Induced Lipodystrophy Syndrome","volume":"87","author":"Agarwal","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11523-017-0504-7","article-title":"Ixazomib: A Review in Relapsed and\/or Refractory Multiple Myeloma","volume":"12","author":"Al-Salama","year":"2017","journal-title":"Target Oncol."},{"key":"B3","unstructured":""},{"key":"B4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","article-title":"Increase in Kelch 13 Polymorphisms in Plasmodium Falciparum, Southern Rwanda","volume":"27","author":"Bergmann","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"B5","first-page":"634","article-title":"Proteasomal Adaptations to FDA-Approved Proteasome Inhibitors: A Potential Mechanism for Drug Resistance","volume":"4","author":"Bo Kim","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"B6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00281-015-0486-4","article-title":"Dysfunction in Protein Clearance by the Proteasome: Impact on Autoinflammatory Diseases","volume":"37","author":"Brehm","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86020","article-title":"Additive Loss-of-Function Proteasome Subunit Mutations in CANDLE\/PRAAS Patients Promote Type I IFN Production","volume":"1126","author":"Brehm","year":"2016","journal-title":"J. Clin. Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-018-06221-1","article-title":"Artemisinin Kills Malaria Parasites by Damaging Proteins and Inhibiting the Proteasome","volume":"9","author":"Bridgford","year":"2018","journal-title":"Nat. Commun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/353355a0","article-title":"Structural and Serological Similarity of MHC-Linked LMP and Proteasome (Multicatalytic Proteinase) Complexes","volume":"353","author":"Brown","year":"1991","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJM195401072500107","article-title":"CASE Records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011","volume":"250","author":"Cabot","year":"1954","journal-title":"N Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4049\/jimmunol.176.2.1053","article-title":"Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation","volume":"176","author":"Chapiro","year":"2006","journal-title":"J. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic Ozonide Drug Candidate OZ439 Offers New Hope for a Single-Dose Cure of Uncomplicated Malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle Cell Lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: From the Lysosome to Ubiquitin and the Proteasome","volume":"6","author":"Ciechanover","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","article-title":"The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target","volume":"3","author":"Cromm","year":"2017","journal-title":"ACS Cent Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0014-5793(89)81441-3","article-title":"The Multicatalytic Proteinase (Prosome) is Ubiquitous From Eukaryotes to Archaebacteria","volume":"251","author":"Dahlmann","year":"1989","journal-title":"FEBS Lett."},{"key":"B17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0014-5793(83)80975-2","volume":"160","author":"Dahlmann","year":"1983","journal-title":"FEBS Lett."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1021\/bi001659k","article-title":"The Ubiquitin-Proteasome Pathway Plays an Essential Role in Proteolysis During Trypanosoma Cruzi Remodeling","volume":"40","author":"De Diego","year":"2001","journal-title":"Biochemistry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jaci.2018.12.1012","article-title":"Novel Proteasome Assembly Chaperone Mutations in PSMG2\/PAC2, Cause the Autoinflammatory Interferonopathy, CANDLE\/Praas4","volume":"143","author":"De Jesus","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on Bortezomib: Second Generation Proteasome Inhibitors as Anti-Cancer Therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discovery Today"},{"key":"B21","doi-asserted-by":"publisher","first-page":"25637","DOI":"10.1074\/jbc.273.40.25637","article-title":"Contribution of Proteasomal Beta-Subunits to the Cleavage of Peptide Substrates Analyzed With Yeast Mutants","volume":"273","author":"Dick","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","article-title":"Proteasomal and Autophagic Degradation Systems","volume":"86","author":"Dikic","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002132","article-title":"Targeting the Cell Stress Response of Plasmodium Falciparum to Overcome Artemisinin Resistance","volume":"13","author":"Dogovski","year":"2015","journal-title":"PloS Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate Versus Quinine in the Treatment of Severe Falciparum Malaria in African Children (AQUAMAT): An Open-Label, Randomised Trial","volume":"376","author":"Dondorp","year":"2010","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10555-017-9698-5","article-title":"Emerging Small Molecule Approaches to Enhance the Antimyeloma Benefit of Proteasome Inhibitors","volume":"36","author":"Driscoll","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/365262a0","article-title":"MHC-Linked LMP Gene Products Specifically Alter Peptidase Activities of the Proteasome","volume":"365","author":"Driscoll","year":"1993","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0092-8674(92)90024-7","article-title":"A Controlled Breakdown: Antigen Processing and the Turnover of Viral Proteins","volume":"68","author":"Driscoll","year":"1992","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.86.3.787","article-title":"Skeletal Muscle Proteasome can Degrade Proteins in an ATP-Dependent Process That Does Not Require Ubiquitin","volume":"86","author":"Driscoll","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1016\/S0021-9258(19)34041-4","article-title":"The Proteasome (Multicatalytic Protease) Is a Component of the 1500-kDa Proteolytic Complex Which Degrades Ubiquitin-Conjugated Proteins","volume":"265","author":"Driscoll","year":"1990","journal-title":"J. Biol. Chem."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential Efficacy of Bortezomib Plus Chemotherapy Within Molecular Subtypes of Diffuse Large B-Cell Lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02756","article-title":"Contribution of the Unfolded Protein Response (UPR) to the Pathogenesis of Proteasome-Associated Autoinflammatory Syndromes (PRAAS)","volume":"10","author":"Ebstein","year":"2019","journal-title":"Front. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrmicro.2017.133","article-title":"Archaea Origin Eukaryotes","volume":"15","author":"Eme","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"CD010678","DOI":"10.1002\/14651858.CD010678.pub3","article-title":"Artemether for Severe Malaria","volume":"6","author":"Esu","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7751","DOI":"10.1073\/pnas.86.20.7751","article-title":"ATP-Dependent Incorporation of 20S Protease Into the 26S Complex That Degrades Proteins Conjugated to Ubiquitin","volume":"86","author":"Eytan","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/331190a0","article-title":"Drosophila Small Cytoplasmic 19S Ribonucleoprotein is Homologous to the Rat Multicatalytic Proteinase","volume":"331","author":"Falkenburg","year":"1988","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome Inhibitor Drugs","volume":"6","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.tibs.2010.05.005","article-title":"The 26S Proteasome: Assembly and Function of a Destructive Machine","volume":"35","author":"Gallastegui","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S Proteasome From Yeast at 2.4\u00c5 Resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib Induces Anti\u2013Multiple Myeloma Immune Response Mediated by cGAS\/STING Pathway Activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B41","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.molcel.2013.08.016","article-title":"Proteasomes Activate Aggresome Disassembly and Clearance by Producing Unanchored Ubiquitin Chains","volume":"51","author":"Hao","year":"2013","journal-title":"Mol. Cell."},{"key":"B42","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ncb3184","article-title":"Proteostasis Control by the Unfolded Protein Response","volume":"17","author":"Hetz","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"B44","first-page":"3071","article-title":"The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding Multiple Myeloma Pathogenesis in the Bone Marrow to Identify New Therapeutic Targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of Selective Small-Molecule HDAC6 Inhibitor for Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.beha.2012.04.007","article-title":"Proteasome Inhibitors in Mantle Cell Lymphoma","volume":"25","author":"Holkova","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1002\/anie.201201616","article-title":"Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development","volume":"51","author":"Huber","year":"2012","journal-title":"Angew Chem Int. Ed"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1021\/acsmedchemlett.6b00496","article-title":"Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit","volume":"8","author":"Johnson","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1128\/AAC.00225-07","article-title":"Peroxide Bond-Dependent Antiplasmodial Specificity of Artemisinin and OZ277 (Rbx11160)","volume":"51","author":"Kaiser","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","article-title":"The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress","volume":"115","author":"Kawaguchi","year":"2003","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome Inhibition for Treatment of Leishmaniasis, Chagas Disease and Sleeping Sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"E6863","DOI":"10.1073\/pnas.1806109115","article-title":"Antimalarial Proteasome Inhibitor Reveals Collateral Sensitivity From Intersubunit Interactions and Fitness Cost of Resistance","volume":"115","author":"Kirkman","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","article-title":"Proteasome Inhibitors: An Expanding Army Attacking a Unique Target","volume":"19","author":"Kisselev","year":"2012","journal-title":"Chem. Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1172\/JCI58414","article-title":"A Mutation in the Immunoproteasome Subunit PSMB8 Causes Autoinflammation and Lipodystrophy in Humans","volume":"121","author":"Kitamura","year":"2011","journal-title":"J. Clin. Invest."},{"key":"B57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/35056572","article-title":"Antigen Processing by the Proteasome","volume":"2","author":"Kloetzel","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7164\/antibiotics.53.105","article-title":"TMC-95a, B, C, and D, Novel Proteasome Inhibitors Produced by Apiospora Montagnei Sacc. TC 1093. Taxonomy, Production, Isolation, and Biological Activities","volume":"53","author":"Koguchi","year":"2000","journal-title":"J. Antibiot"},{"key":"B59","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0962-8924(00)01852-3","article-title":"Aggresomes, Inclusion Bodies and Protein Aggregation","volume":"10","author":"Kopito","year":"2000","journal-title":"Trends Cell Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.trsl.2018.04.007","article-title":"The Proteasome as a Target to Combat Malaria: Hits and Misses","volume":"198","author":"Krishnan","year":"2018","journal-title":"Transl. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent Activity of Carfilzomib, a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway, Against Preclinical Models of Multiple Myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 Study of Weekly Dosing With the Investigational Oral Proteasome Inhibitor Ixazomib in Relapsed\/Refractory Multiple Myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1182\/blood-2008-07-167767","article-title":"Many Facets of Bortezomib Resistance\/Susceptibility","volume":"112","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1021\/acs.jmedchem.7b00671","article-title":"Development of a Potent Inhibitor of the Plasmodium Proteasome With Reduced Mammalian Toxicity","volume":"60","author":"LaMonte","year":"2017","journal-title":"J. Med. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.chembiol.2012.09.019","article-title":"Validation of the Proteasome as a Therapeutic Target in Plasmodium Using an Epoxyketone Inhibitor With Parasite-Specific Toxicity","volume":"19","author":"Li","year":"2012","journal-title":"Chem. Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1021\/cb5001263","article-title":"Assessing Subunit Dependency of the Plasmodium Proteasome Using Small Molecule Inhibitors and Active Site Probes","volume":"9","author":"Li","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nature16936","article-title":"Structure- and Function-Based Design of Plasmodium-Selective Proteasome Inhibitors","volume":"530","author":"Li","year":"2016","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The Role of Bortezomib in Newly Diagnosed Diffuse Large B Cell Lymphoma: A Meta-Analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann. Hematol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"9968","DOI":"10.1021\/ja400021x","article-title":"N,C-Capped Dipeptides With Selectivity for Mycobacterial Proteasome Over Human Proteasomes: Role of S3 and S1 Binding Pockets","volume":"135","author":"Lin","year":"2013","journal-title":"J. Am. Chem. Soc"},{"key":"B70","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.abb.2010.06.009","article-title":"Fellutamide B is a Potent Inhibitor of the Mycobacterium Tuberculosis Proteasome","volume":"501","author":"Lin","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"B71","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nature08357","article-title":"Inhibitors Selective for Mycobacterial Versus Human Proteasomes","volume":"461","author":"Lin","year":"2009","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1242\/jcs.00408","article-title":"The Unfolded Protein Response","volume":"116","author":"Liu","year":"2003","journal-title":"J. Cell Sci."},{"key":"B73","first-page":"533","article-title":"Crystal Structure of the 20S Proteasome From the Archaeon T. Acidophilum at 3.4 \u00c5 Resolution","author":"L\u00f6we","year":"2015"},{"key":"B74","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1073\/pnas.1817752116","article-title":"Cryo-EM Structures of the Archaeal PAN-Proteasome Reveal an Around-the-Ring ATPase Cycle","volume":"116","author":"Majumder","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B75","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00436-002-0601-z","article-title":"Effect of Proteasome Inhibitors on the Growth, Encystation, and Excystation of Entamoeba Histolytica and Entamoeba Invadens","volume":"88","author":"Makioka","year":"2002","journal-title":"Parasitol. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1073\/pnas.86.8.2597","article-title":"Involvement of the Proteasome in Various Degradative Processes in Mammalian Cells","volume":"86","author":"Matthews","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B77","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrmicro2696","article-title":"Proteasomes and Protein Conjugation Across Domains of Life","volume":"10","author":"Maupin-Furlow","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/ijd.12695","article-title":"Proteasome-Associated Autoinflammatory Syndromes: Advances in Pathogeneses, Clinical Presentations, Diagnosis, and Management","volume":"54","author":"McDermott","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.20517\/cdr.2021.93","article-title":"Overcoming Drug Resistance by Targeting Protein Homeostasis in Multiple Myeloma","volume":"4","author":"Moscvin","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"B81","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2018-eular.1100","article-title":"Kzr-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)","volume":"77","author":"Muchamuel","year":"2018","journal-title":"Ann. Rheumatic Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-Analysis","author":"Munshi","year":"2017"},{"key":"B83","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.pt.2017.05.009","article-title":"Protein Degradation Systems as Antimalarial Therapeutic Targets","volume":"33","author":"Ng","year":"2017","journal-title":"Trends Parasitol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/092986708783330692","article-title":"Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications","volume":"15","author":"Olzmann","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome Inhibitors in Cancer Therapy: Lessons From the First Decade. Clin","volume":"14","author":"Orlowski","year":"2008","journal-title":"Cancer Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"New Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-Generation Proteasome Inhibitors for Cancer Therapy","volume":"198","author":"Park","year":"2018","journal-title":"Transl. Res."},{"key":"B88","first-page":"55","volume":"19","author":"Paugam","year":"2003","journal-title":"Characterization role protozoan parasite proteasomes Trends Parasitol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"17050","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ajhg.2018.04.010","article-title":"Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome","volume":"102","author":"Poli","year":"2018","journal-title":"Am. J. Hum. Genet."},{"key":"B91","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification and Management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1073\/pnas.82.22.7545","article-title":"Purification of Neutral Lens Endopeptidase: Close Similarities to a Neutral Proteinase in Pituitary","volume":"82","author":"Ray","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/bloodadvances.2018022095","article-title":"Safety and Efficacy of an Oncolytic Viral Strategy Using Bortezomib With ICE\/R in Relapsed\/Refractory HIV-Positive Lymphomas","volume":"2","author":"Reid","year":"2018","journal-title":"Blood Advances"},{"key":"B94","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"LYM-3002 Investigators Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0166-6851(99)00110-3","article-title":"The Leishmania Mexicana Proteasome","volume":"103","author":"Robertson","year":"1999","journal-title":"Mol. Biochem. Parasitol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 Inhibition With Baricitinib in the Treatment of Autoinflammatory Interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02386","article-title":"Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis","volume":"9","author":"Schmidt","year":"2018","journal-title":"Front. Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","article-title":"The Mammalian Unfolded Protein Response","volume":"74","author":"Schroder","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1017\/S0031182099006071","article-title":"Proteasome Inhibitors Block Intracellular Growth and Replication of Toxoplasma Gondii","volume":"121","author":"Shaw","year":"2000","journal-title":"Parasitology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007722","article-title":"Covalent Plasmodium Falciparum-Selective Proteasome Inhibitors Exhibit a Low Propensity for Generating Resistance In Vitro and Synergize With Multiple Antimalarial Agents","volume":"15","author":"Stokes","year":"2019","journal-title":"PloS Pathog."},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02900","article-title":"Molecular Insight Into the IRE1\u03b1-Mediated Type I Interferon Response Induced by Proteasome Impairment in Myeloid Cells of the Brain","volume":"10","author":"Studencka-Turski","year":"2019","journal-title":"Front. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/acsinfecdis.6b00172","article-title":"Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium Tuberculosis Proteasome","volume":"3","author":"Totaro","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1128\/AAC.00742-12","article-title":"Broad-Spectrum Antimalarial Activity of Peptido Sulfonyl Fluorides, a New Class of Proteasome Inhibitors","volume":"57","author":"Tschan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1080\/07391102.2020.1835722","article-title":"Development of Potential Proteasome Inhibitors Against Mycobacterium Tuberculosis","volume":"40","author":"Tyagi","year":"2022","journal-title":"J. Biomol Struct. Dyn"},{"key":"B105","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B106","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","article-title":"Determinants of Dihydroartemisinin-Piperaquine Treatment Failure in Plasmodium Falciparum Malaria in Cambodia, Thailand, and Vietnam: A Prospective Clinical, Pharmacological, and Genetic Study","volume":"19","author":"Van de Pluijim","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jaci.2021.07.039","article-title":"Hematopoietic Stem Cell Transplantation in a Patient With Proteasome-Associated Autoinflammatory Syndrome (PRAAS)","volume":"149","author":"Verhoeven","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1471-4159.1980.tb07873.x","article-title":"Cation-Sensitive Neutral Endopeptidase: Isolation and Specificity of the Bovine Pituitary Enzyme","volume":"35","author":"Wilk","year":"1980","journal-title":"J. Neurochem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1471-4159.1983.tb08056.x","article-title":"Evidence That Pituitary Cation-Sensitive Neutral Endopeptidase is a Multicatalytic Protease Complex","volume":"40","author":"Wilk","year":"1983","journal-title":"J. Neurochem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/ajt.15634","article-title":"Proteasomal Adaptations Underlying Carfilzomib-Resistance in Human Bone Marrow Plasma Cells","author":"Woodle","year":"2020"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1681\/ASN.2017040443","article-title":"Targeting Plasma Cells With Proteasome Inhibitors: Principles From Primates","volume":"28","author":"Woodle","year":"2017","journal-title":"Jour Amer Soc Nephrol"},{"key":"B113","unstructured":"World Health OrganizationWorld Malaria Report 20202020"},{"key":"B114","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1021\/acs.jmedchem.8b01161","article-title":"Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium Falciparum Proteasome","volume":"61","author":"Xie","year":"2018","journal-title":"J. Med. Chem."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107213118","article-title":"Design of Proteasome Inhibitors With Oral Efficacy In Vivo Against Plasmodium Falciparum and Selectivity Over the Human Proteasome","volume":"118","author":"Xie","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111646","article-title":"Immunoproteasome-Selective Inhibitors: An Overview of Recent Developments as Potential Drugs for Hematologic Malignancies and Autoimmune Diseases","volume":"182","author":"Xi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B117","doi-asserted-by":"publisher","first-page":"11424","DOI":"10.1021\/jacs.8b06656","article-title":"Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors","volume":"140","author":"Yoo","year":"2018","journal-title":"J. Am. Chem. Soc"},{"key":"B118","doi-asserted-by":"publisher","first-page":"CD010927","DOI":"10.1002\/14651858.CD010927","article-title":"Dihydroartemisinin-Piperaquine for Treating Uncomplicated Plasmodium Falciparum Malaria","volume":"2014","author":"Zani","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B119","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1002\/anie.202015845","article-title":"Development of a Highly Selective Plasmodium Falciparum Proteasome Inhibitor With Anti-Malaria Activity in Humanized Mice","volume":"60","author":"Zhan","year":"2021","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010058","article-title":"Microbial Proteasomes as Drug Targets","volume":"17","author":"Zhang","year":"2021","journal-title":"PloS Pathog."},{"key":"B121","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/10428194.2021.1999437","article-title":"A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Relapsed\/Refractory iMCD","volume":"63","author":"Zhang","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B122","doi-asserted-by":"publisher","first-page":"9246","DOI":"10.1021\/acs.jmedchem.9b01187","article-title":"Selective Phenylimidazole-Based Inhibitors of the Mycobacterium Tuberculosis Proteasome","volume":"62","author":"Zhan","year":"2019","journal-title":"J. Med. Chem."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.925804\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T15:52:46Z","timestamp":1657209166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.925804\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":122,"alternative-id":["10.3389\/fcimb.2022.925804"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.925804","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]},"article-number":"925804"}}